Ionis Pharmaceuticals (IONS) Net Income towards Common Stockholders (2009 - 2026)

Ionis Pharmaceuticals' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at -$92.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 37.03% year-over-year to -$92.5 million; the TTM figure through Mar 2026 stood at $26.0 million (up 105.66% YoY), while the FY2025 annual figure was -$383.0 million, up 15.75% from the prior year.
• Net Income towards Common Stockholders was -$92.5 million for Q1 2026 at Ionis Pharmaceuticals, down from $123.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $123.6 million in Q2 2025 to a low of -$147.4 million in Q3 2023.
• Historically, Net Income towards Common Stockholders has averaged -$71.3 million across 5 years, with a median of -$92.5 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 1033.67% in 2024, then jumped 286.45% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$53.0 million in 2022, then jumped by 82.51% to -$9.3 million in 2023, then plunged by 1033.67% to -$105.0 million in 2024, then surged by 217.65% to $123.6 million in 2025, then tumbled by 174.89% to -$92.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$92.5 million (Q1 2026), $123.6 million (Q4 2025), and -$128.6 million (Q3 2025), per Business Quant data.